Orbit Genomics Partners With Icahn School of Medicine at Mount Sinai

We are thrilled to announce that Orbit Genomics has partnered with the esteemed Icahn School of Medicine at Mount Sinai for optimization of our revolutionary lung cancer diagnostic platform. This collaboration will allow us to further advance the accuracy and reliability of our test, which will have significant implications for the future of cancer diagnosis and treatment.

At Orbit Genomics, we are committed to developing innovative solutions that can help improve patient outcomes and make a real difference in the fight against cancer. Our work with Mount Sinai represents a major step towards achieving these goals and we look forward to sharing more updates on our progress in the coming months.

Thank you for your support and stay tuned for more exciting news from Orbit Genomics!